Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Free Report) – Investment analysts at Wedbush issued their FY2023 earnings estimates for Monte Rosa Therapeutics in a report released on Wednesday, February 14th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($2.63) per share for the year. Wedbush currently has a “Outperform” rating and […]
Related Keywords
Canada , , Monte Rosa Therapeutics Inc , Barclays Plc , Sg Americas Securities , Royal Bank , Life Insurance Co , Nasdaq , Ameritas Investment Partners Inc , Monte Rosa Therapeutics , Free Report , Monte Rosa Therapeutic , Rosa Therapeutics , Investment Partners , Get Free Report , Monte Rosa Therapeutics Daily , Nasdaq Glue , Glue , Medical , Earnings Estimates , Wedbush ,
vimarsana.com © 2020. All Rights Reserved.